{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T10:44:48Z","timestamp":1795085088000,"version":"4.10.2"},"reference-count":63,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,9]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>This review provides updates regarding the role of interferon (IFN) in juvenile dermatomyositis (JDM), including comparison to interferonopathies and therapeutic implications.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>Transcriptomic and protein-based studies in different tissues and peripheral IFN-\u03b1 assessment have demonstrated the importance of the dysregulated IFN pathway in JDM. Additional studies have validated IFN-regulated gene and protein expression correlation with disease activity in blood and muscle, with potential to predict flares. Type I and II IFN both are dysregulated in peripheral blood and muscle, with more type I IFN in skin. Muscle studies connects hypoxia to IFN production and IFN to vascular dysfunction and muscle atrophy. JDM overlaps with interferonopathy phenotype and IFN signature. There are multiple case reports and case series noting decreased IFN markers and clinical improvement in refractory JDM with Janus kinase (JAK) inhibitors.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>Studies confirm IFN, particularly type I and II IFN, is an important part of JDM pathogenesis by the level of dysregulation and correlation with disease activity, as well as IFN recapitulating key JDM muscle pathology. Smaller studies indicate there may be differences by myositis-specific autoantibody group, but validation is needed. JAK inhibitors are a promising therapy as they can inhibit IFN signaling, but further study is needed regarding which patients will benefit, dosing, and safety monitoring.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/bor.0000000000000816","type":"journal-article","created":{"date-parts":[[2021,7,7]],"date-time":"2021-07-07T09:03:28Z","timestamp":1625648608000},"page":"371-377","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":49,"title":["Updates on interferon in juvenile dermatomyositis: pathogenesis and therapy"],"prefix":"10.1097","volume":"33","author":[{"given":"Hanna","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,7,6]]},"reference":[{"key":"R1-20250526","doi-asserted-by":"crossref","first-page":"2951","DOI":"10.3389\/fimmu.2018.02951","article-title":"Systemic and tissue inflammation in juvenile dermatomyositis: from pathogenesis to the quest for monitoring tools","volume":"9","author":"Wienke","year":"2018","journal-title":"Front Immunol"},{"key":"R2-20250526","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/joim.12444","article-title":"The juvenile idiopathic inflammatory myopathies: pathogenesis, clinical and autoantibody phenotypes, and outcomes","volume":"280","author":"Rider","year":"2016","journal-title":"J Intern Med"},{"key":"R3-20250526","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jaut.2017.06.007","article-title":"Autoantibodies in juvenile-onset myositis: their diagnostic value and associated clinical phenotype in a large UK cohort","volume":"84","author":"Tansley","year":"2017","journal-title":"J Autoimmun"},{"key":"R4-20250526","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.semarthrit.2018.03.016","article-title":"Medications received by patients with juvenile dermatomyositis","volume":"48","author":"Kishi","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"R5-20250526","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1177\/1759720X11424460","article-title":"Juvenile dermatomyositis: new insights and new treatment strategies","volume":"4","author":"Martin","year":"2012","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"R6-20250526","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/nrrheum.2018.48","article-title":"Risk factors and disease mechanisms in myositis","volume":"14","author":"Miller","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"R7-20250526","doi-asserted-by":"crossref","first-page":"4154","DOI":"10.4049\/jimmunol.168.8.4154","article-title":"Gene expression profiling in DQA1\u22170501+ children with untreated dermatomyositis: a novel model of pathogenesis","volume":"168","author":"Tezak","year":"2002","journal-title":"J Immunol"},{"key":"R8-20250526","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2119\/2006-00085.Baechler","article-title":"An interferon signature in the peripheral blood of dermatomyositis patients is associated with disease activity","volume":"13","author":"Baechler","year":"2007","journal-title":"Mol Med"},{"key":"R9-20250526","doi-asserted-by":"crossref","first-page":"a028423","DOI":"10.1101\/cshperspect.a028423","article-title":"The interferon (IFN) class of cytokines and the IFN regulatory factor (IRF) transcription factor family","volume":"10","author":"Negishi","year":"2018","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"R10-20250526","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.cytogfr.2015.01.001","article-title":"New perspectives on type I IFNs in cancer","volume":"26","author":"Gajewski","year":"2015","journal-title":"Cytokine Growth Factor Rev"},{"key":"R11-20250526","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1002\/art.24555","article-title":"Elevated serum interferon-alpha activity in juvenile dermatomyositis: associations with disease activity at diagnosis and after thirty-six months of therapy","volume":"60","author":"Niewold","year":"2009","journal-title":"Arthritis Rheum"},{"key":"R12-20250526","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1089\/jir.2017.0127","article-title":"Development of a validated interferon score using nanostring technology","volume":"38","author":"Kim","year":"2018","journal-title":"J Interferon Cytokine Res"},{"key":"R13-20250526","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/JLB.5RI0218-084R","article-title":"Translational and clinical advances in JAK-STAT biology: the present and future of jakinibs","volume":"104","author":"Gadina","year":"2018","journal-title":"J Leukoc Biol"},{"key":"R14-20250526","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1002\/art.40800","article-title":"Muscle expression of Type I and Type II interferons is increased in juvenile dermatomyositis and related to clinical and histologic features","volume":"71","author":"Moneta","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"R15-20250526","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/ana.21805","article-title":"Interferon-stimulated gene 15 (ISG15) conjugates proteins in dermatomyositis muscle with perifascicular atrophy","volume":"67","author":"Salajegheh","year":"2010","journal-title":"Ann Neurol"},{"key":"R16-20250526","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1002\/art.41625","article-title":"From diagnosis to prognosis: revisiting the meaning of muscle ISG15 overexpression in Juvenile inflammatory myopathies","volume":"73","author":"Hou","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"R17-20250526","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1186\/ar3531","article-title":"Type I interferon pathway in adult and juvenile dermatomyositis","volume":"13","author":"Baechler","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"R18-20250526","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1111\/bjd.15006","article-title":"Correlation of cutaneous disease activity with type 1 interferon gene signature and interferon beta in dermatomyositis","volume":"176","author":"Huard","year":"2017","journal-title":"Br J Dermatol"},{"key":"R19-20250526","doi-asserted-by":"crossref","first-page":"3436","DOI":"10.1002\/art.24936","article-title":"Interleukin-6 and type I interferon-regulated genes and chemokines mark disease activity in dermatomyositis","volume":"60","author":"Bilgic","year":"2009","journal-title":"Arthritis Rheum"},{"key":"R20-20250526","doi-asserted-by":"crossref","first-page":"e29161","DOI":"10.1371\/journal.pone.0029161","article-title":"Interferon and biologic signatures in dermatomyositis skin: specificity and heterogeneity across diseases","volume":"7","author":"Wong","year":"2012","journal-title":"PLoS One"},{"key":"R21-20250526","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1002\/art.41615","article-title":"Comparison of lesional Juvenile myositis and lupus skin reveals overlapping yet unique disease pathophysiology","volume":"73","author":"Turnier","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"R22-20250526","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1002\/acr2.11081","article-title":"Gene expression meta-analysis reveals concordance in gene activation, pathway, and cell-type enrichment in dermatomyositis target tissues","volume":"1","author":"Neely","year":"2019","journal-title":"ACR Open Rheumatol"},{"key":"R23-20250526","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.clim.2006.05.011","article-title":"MxA gene expression in juvenile dermatomyositis peripheral blood mononuclear cells: association with muscle involvement","volume":"120","author":"O\u2019Connor","year":"2006","journal-title":"Clin Immunol"},{"key":"R24-20250526","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s13075-020-02160-9","article-title":"Expression of interferon-regulated genes in juvenile dermatomyositis versus Mendelian autoinflammatory interferonopathies","volume":"22","author":"Kim","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"R25-20250526","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/nrrheum.2018.33","article-title":"Update on outcome assessment in myositis","volume":"14","author":"Rider","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"R26-20250526","doi-asserted-by":"crossref","first-page":"4078","DOI":"10.1002\/art.34659","article-title":"Changes in novel biomarkers of disease activity in juvenile and adult dermatomyositis are sensitive biomarkers of disease course","volume":"64","author":"Reed","year":"2012","journal-title":"Arthritis Rheum"},{"key":"R27-20250526","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.3389\/fimmu.2018.01372","article-title":"CD19(+)CD24(hi)CD38(hi) B cells are expanded in Juvenile dermatomyositis and exhibit a pro-inflammatory phenotype after activation through toll-like receptor 7 and interferon-alpha","volume":"9","author":"Piper","year":"2018","journal-title":"Front Immunol"},{"key":"R28-20250526","doi-asserted-by":"crossref","first-page":"3175","DOI":"10.1002\/art.21303","article-title":"Association between lack of angiogenic response in muscle tissue and high expression of angiostatic ELR-negative CXC chemokines in patients with juvenile dermatomyositis: possible link to vasculopathy","volume":"52","author":"Fall","year":"2005","journal-title":"Arthritis Rheum"},{"key":"R29-20250526","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1002\/art.27529","article-title":"Lesional and nonlesional skin from patients with untreated juvenile dermatomyositis displays increased numbers of mast cells and mature plasmacytoid dendritic cells","volume":"62","author":"Shrestha","year":"2010","journal-title":"Arthritis Rheum"},{"key":"R30-20250526","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/nan.12498","article-title":"Expression of myxovirus-resistance protein A: a possible marker of muscle disease activity and autoantibody specificities in juvenile dermatomyositis","volume":"45","author":"Soponkanaporn","year":"2019","journal-title":"Neuropathol Appl Neurobiol"},{"key":"R31-20250526","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1046\/j.1442-200x.2001.01367.x","article-title":"Elevated serum levels of soluble interleukin-2 receptor in juvenile dermatomyositis","volume":"43","author":"Kobayashi","year":"2001","journal-title":"Pediatr Int"},{"key":"R32-20250526","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1136\/adc.69.2.232","article-title":"Correlation of serum neopterin concentrations with disease activity in juvenile dermatomyositis","volume":"69","author":"De Benedetti","year":"1993","journal-title":"Arch Dis Child"},{"key":"R33-20250526","doi-asserted-by":"crossref","first-page":"e92171","DOI":"10.1371\/journal.pone.0092171","article-title":"Increased levels of eotaxin and MCP-1 in juvenile dermatomyositis median 16.8\u200ayears after disease onset; associations with disease activity, duration and organ damage","volume":"9","author":"Sanner","year":"2014","journal-title":"PLoS One"},{"key":"R34-20250526","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/acr2.1011","article-title":"Interferon chemokine score and other cytokine measures track with changes in disease activity in patients with juvenile and adult dermatomyositis","volume":"1","author":"Crowson","year":"2019","journal-title":"ACR Open Rheumatol"},{"key":"R35-20250526","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1002\/art.38676","article-title":"Correlation of CXCL10, tumor necrosis factor receptor type II, and galectin 9 with disease activity in juvenile dermatomyositis","volume":"66","author":"Bellutti Enders","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"R36-20250526","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1002\/art.39200","article-title":"Analysis of published criteria for clinically inactive disease in a large juvenile dermatomyositis cohort shows that skin disease is underestimated","volume":"67","author":"Almeida","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"R37-20250526","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1002\/art.40881","article-title":"Galectin-9 and CXCL10 as biomarkers for disease activity in juvenile dermatomyositis: a longitudinal cohort study and multicohort validation","volume":"71","author":"Wienke","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"R38-20250526","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1002\/art.41236","article-title":"Endothelial and inflammation biomarker profiles at diagnosis reflecting clinical heterogeneity and serving as a prognostic tool for treatment response in two independent cohorts of patients with juvenile dermatomyositis","volume":"72","author":"Wienke","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"R39-20250526","doi-asserted-by":"crossref","DOI":"10.1002\/art.41625","article-title":"Response to: \u2018Myositis-specific autoantibodies as relevant adjusting variables in myositis research\u2019 by Pinal Fernandez et al. Correspondence on \u2018From diagnosis to prognosis: Revisiting the meaning of muscle ISG15 overexpression in juvenile inflammatory myopathies\u2019","author":"Hou","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"R40-20250526","doi-asserted-by":"crossref","DOI":"10.1002\/art.41705","article-title":"Myositis-specific autoantibodies as relevant adjusting variables in myositis research","author":"Pinal-Fernandez","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"R41-20250526","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1084\/jem.20161451","article-title":"Detection of interferon alpha protein reveals differential levels and cellular sources in disease","volume":"214","author":"Rodero","year":"2017","journal-title":"J Exp Med"},{"key":"R42-20250526","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1093\/rheumatology\/kez508","article-title":"Inhibition of IFNalpha secretion in cells from patients with juvenile dermatomyositis under TBK1 inhibitor treatment revealed by single-molecular assay technology","volume":"59","author":"Gitiaux","year":"2020","journal-title":"Rheumatology"},{"key":"R43-20250526","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1146\/annurev-virology-092818-015756","article-title":"Interferon-stimulated genes: what do they all do?","volume":"6","author":"Schoggins","year":"2019","journal-title":"Annu Rev Virol"},{"key":"R44-20250526","doi-asserted-by":"crossref","first-page":"4239","DOI":"10.1073\/pnas.1114981109","article-title":"Systematic identification of type I and type II interferon-induced antiviral factors","volume":"109","author":"Liu","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"R45-20250526","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1172\/JCI129301","article-title":"Distinct interferon signatures and cytokine patterns define additional systemic autoinflammatory diseases","volume":"130","author":"de Jesus","year":"2020","journal-title":"J Clin Investig"},{"key":"R46-20250526","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.immuni.2010.12.012","article-title":"Human blood CXCR5(+)CD4(+) T cells are counterparts of T follicular cells and contain specific subsets that differentially support antibody secretion","volume":"34","author":"Morita","year":"2011","journal-title":"Immunity"},{"key":"R47-20250526","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1136\/annrheumdis-2012-201822","article-title":"Whole microvascular unit deletions in dermatomyositis","volume":"72","author":"Gitiaux","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"R48-20250526","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1002\/ana.410270402","article-title":"Microvascular changes in early and advanced dermatomyositis: a quantitative study","volume":"27","author":"Emslie-Smith","year":"1990","journal-title":"Ann Neurol"},{"key":"R49-20250526","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jneuroim.2015.06.009","article-title":"Role of Toll-like receptors and retinoic acid inducible gene I in endogenous production of type I interferon in dermatomyositis","volume":"285","author":"Li","year":"2015","journal-title":"J Neuroimmunol"},{"key":"R50-20250526","doi-asserted-by":"crossref","first-page":"8595","DOI":"10.1038\/s41598-017-09309-8","article-title":"Hypoxia triggers IFN-I production in muscle: Implications in dermatomyositis","volume":"7","author":"De Luna","year":"2017","journal-title":"Sci Rep"},{"key":"R51-20250526","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1093\/brain\/awy105","article-title":"JAK inhibitor improves type I interferon induced damage: proof of concept in dermatomyositis","volume":"141","author":"Ladislau","year":"2018","journal-title":"Brain"},{"key":"R52-20250526","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1002\/art.40328","article-title":"Myogenic progenitor cells exhibit Type I interferon-driven proangiogenic properties and molecular signature during juvenile dermatomyositis","volume":"70","author":"Gitiaux","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"R53-20250526","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1007\/s00109-016-1465-5","article-title":"Insights from mendelian interferonopathies: comparison of CANDLE, SAVI with AGS, Monogenic Lupus","volume":"94","author":"Kim","year":"2016","journal-title":"J Mol Med"},{"key":"R54-20250526","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1172\/JCI98814","article-title":"JAK1\/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies","volume":"128","author":"Sanchez","year":"2018","journal-title":"J Clin Investig"},{"key":"R55-20250526","article-title":"Janus kinase (JAK) inhibition with baricitinib in refractory juvenile dermatomyositis","author":"Kim","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"R56-20250526","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1136\/annrheumdis-2020-218582","article-title":"Janus kinase inhibitor significantly improved rash and muscle strength in juvenile dermatomyositis","volume":"80","author":"Ding","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"R57-20250526","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1093\/brain\/awz293","article-title":"Treatment of anti-MDA5 autoantibody-positive juvenile dermatomyositis using tofacitinib","volume":"142","author":"Sabbagh","year":"2019","journal-title":"Brain"},{"key":"R58-20250526","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1093\/brain\/awz005","article-title":"Janus kinase 1\/2 inhibition with baricitinib in the treatment of juvenile dermatomyositis","volume":"142","author":"Papadopoulou","year":"2019","journal-title":"Brain"},{"key":"R59-20250526","doi-asserted-by":"crossref","first-page":"e80","DOI":"10.1093\/brain\/awy255","article-title":"A child with severe juvenile dermatomyositis treated with ruxolitinib","volume":"141","author":"Aeschlimann","year":"2018","journal-title":"Brain"},{"key":"R60-20250526","article-title":"JAK inhibitors are effective in a subset of patients with juvenile dermatomyositis: a monocentric retrospective study","author":"Voyer","year":"2021","journal-title":"Rheumatology"},{"key":"R61-20250526","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1093\/rheumatology\/keaa558","article-title":"Successful management with Janus kinase inhibitor tofacitinib in refractory juvenile dermatomyositis: a pilot study and literature review","volume":"60","author":"Yu","year":"2021","journal-title":"Rheumatology"},{"key":"R62-20250526","doi-asserted-by":"crossref","first-page":"e140","DOI":"10.1093\/rheumatology\/keaa360","article-title":"A striking treatment option for recalcitrant calcinosis in juvenile dermatomyositis: tofacitinib citrate","volume":"59","author":"Sozeri","year":"2020","journal-title":"Rheumatology"},{"key":"R63-20250526","doi-asserted-by":"crossref","first-page":"e136","DOI":"10.1093\/rheumatology\/keaa657","article-title":"Interferon signature guiding therapeutic decision making: ruxolitinib as first-line therapy for severe juvenile dermatomyositis?","volume":"60","author":"Heinen","year":"2021","journal-title":"Rheumatology"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000816","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T21:20:20Z","timestamp":1748294420000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000816"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,6]]},"references-count":63,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000000816","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,6]]}}}